Leavell Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Leavell Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$241K	–	594
2025 Q2	$241K	Hold	1,000	–	–	0.01%	529
2025 Q1	$244K	Sell	1,000 -500	-33%	-$150K	0.01%	500
2024 Q4	$493K	Hold	1,500	–	–	0.02%	377
2024 Q3	$502K	Hold	1,500	–	–	0.03%	377
2024 Q2	$410K	Hold	1,500	–	–	0.02%	387
2024 Q1	$519K	Hold	1,500	–	–	0.03%	346
2023 Q4	$484K	Hold	1,500	–	–	0.03%	335
2023 Q3	$538K	Hold	1,500	–	–	0.04%	324
2023 Q2	$569K	Hold	1,500	–	–	0.04%	315
2023 Q1	$719K	Hold	1,500	–	–	0.05%	285
2022 Q4	$631K	Hold	1,500	–	–	0.05%	295
2022 Q3	$626K	Hold	1,500	–	–	0.05%	284
2022 Q2	$742K	Hold	1,500	–	–	0.06%	266
2022 Q1	$845K	Sell	1,500 -200	-12%	-$121K	0.06%	256
2021 Q4	$1.28M	Hold	1,700	–	–	0.09%	209
2021 Q3	$1.27M	Hold	1,700	–	–	0.09%	190
2021 Q2	$971K	Hold	1,700	–	–	0.08%	204
2021 Q1	$971K	Hold	1,700	–	–	0.08%	204
2020 Q4	$991K	Hold	1,700	–	–	0.09%	193
2020 Q3	$876K	Hold	1,700	–	–	0.08%	195
2020 Q2	$768K	Hold	1,700	–	–	0.07%	204
2020 Q1	$596K	Hold	1,700	–	–	0.07%	207
2019 Q4	$629K	Hold	1,700	–	–	0.06%	242
2019 Q3	$566K	Hold	1,700	–	–	0.06%	251
2019 Q2	$531K	Hold	1,700	–	–	0.06%	255
2019 Q1	$520K	Hold	1,700	–	–	0.06%	251
2018 Q4	$395K	Hold	1,700	–	–	0.05%	265
2018 Q3	$532K	Hold	1,700	–	–	0.06%	248
2018 Q2	$491K	Hold	1,700	–	–	0.06%	257
2018 Q1	$425K	Buy	1,700 +400	+31%	+$102K	0.05%	275
2017 Q4	$310K	Hold	1,300	–	–	0.04%	314
2017 Q3	$289K	Hold	1,300	–	–	0.04%	312
2017 Q2	$294K	Hold	1,300	–	–	0.04%	317
2017 Q1	$259K	Sell	1,300 -1,200	-48%	-$231K	0.03%	326
2016 Q4	$456K	Hold	2,500	–	–	0.06%	251
2016 Q3	$410K	Hold	2,500	–	–	0.06%	262
2016 Q2	$358K	Hold	2,500	–	–	0.05%	282
2016 Q1	$342K	Hold	2,500	–	–	0.05%	279
2015 Q4	$347K	Hold	2,500	–	–	0.05%	280
2015 Q3	$336K	Hold	2,500	–	–	0.05%	288
2015 Q2	$377K	Hold	2,500	–	–	0.06%	286
2015 Q1	$338K	Hold	2,500	–	–	0.05%	309
2014 Q4	$301K	Hold	2,500	–	–	0.05%	321
2014 Q3	$283K	Hold	2,500	–	–	0.05%	329
2014 Q2	$299K	Hold	2,500	–	–	0.05%	319
2014 Q1	$320K	Hold	2,500	–	–	0.05%	297
2013 Q4	$309K	Hold	2,500	–	–	0.05%	300
2013 Q3	$294K	Hold	2,500	–	–	0.05%	306
2013 Q2	$280K	Buy	+2,500	New	+$293K	0.05%	303

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Leavell Investment Management's BIO Position: Q3 2025 in Review

Leavell Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 1,000 shares — an estimated $241K sold.

Leavell Investment Management first reported a position in BIO in Q2 2013 and held it in 49 quarters. The position peaked at $1.28M in Q4 2021. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

Leavell Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
Leavell Investment Management sold 1,000 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $241K.
Leavell Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 49 quarters.
Leavell Investment Management's Bio-Rad Laboratories Class A position peaked at $1.28M in Q4 2021.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Leavell Investment Management's 13F filing for Q3 2025, filed 28 Oct 2025.